The requirement for receptor components and the signalling effector, signal transducer and activator of transcription (STAT) 5A/5B, was assessed genetically in a lymphoma development model induced by interleukin-7 (IL-7). This growth factor for T-and B-cell progenitors and mature lymphocytes activates survival and proliferative pathways including Bcl-2, phosphatidylinositol-3 kinase and STAT5. Overexpression of IL-7 in vivo causes early mortality from lymphoma development. Mice overexpressing IL-7 that were heterozygous for the IL-7Ra subunit showed improved survival compared to wild-type mice. In addition, STAT5A/5B þ /À compound heterozygous mice with one targeted allele each of STAT5A and STAT5B showed striking amelioration of IL-7-induced mortality and disease development. STAT5A/5B þ /À compound heterozygous mice were otherwise normal in stem cell and lymphocyte development and cellularity. Lower STAT5 protein levels accompanied the reduction in STAT5A/5B copy number, which suggests that STAT5 haploinsufficiency is a modifier of IL-7 signal strength.
Cytokines are key regulators of cells by engaging appropriate receptors and triggering downstream signalling events that govern proliferation, survival, differentiation and mobilization. Interleukin-7 (IL-7) is an essential, nonredundant growth factor for early T-and B-cell precursors (Grabstein et al., 1993; Sudo et al., 1993) and exerts effects on mature peripheral T cells (Chazen et al., 1989; Schluns et al., 2000) . IL-7 acts on target cells by interacting with the IL-7 receptor (IL-7R), a heterodimer comprised of the IL-7Ra chain and the common g (gc) chain. In mice lacking IL-7, its a receptor subunit (IL-7Ra), or the gc chain, pro-T cells die in the thymus, resulting in an early block in thymopoiesis, and murine pro-B cells fail to progress resulting in overall lymphopenia (reviewed in Hofmeister et al., 1999) . Deficiency in IL-7 signalling accounts for the severe T-cell immunodeficiency seen in human Xlinked severe-combined immunodeficiency (X-SCID) (Noguchi et al., 1993; Kondo et al., 1994) and (Puel et al., 1998) . While loss of IL-7 causes immunodeficiency, overexpression of IL-7 results in neoplasias. Mouse models that overexpress IL-7 show phenotypes ranging from increased levels of T and B cells (Samaridis et al., 1991) to lymphoproliferation and lymphomas, in addition to dermal lymphoid infiltration (Fisher et al., 1993; Rich et al., 1993; Uehira et al., 1993; Williams et al., 1997) . The Tg IL-7 mouse strain used herein bears some features seen in human cutaneous T-cell lymphomas (Rich et al., 1993) . IL-7's involvement in neoplasias is also suggested by its role as a trophic factor for Sezary lymphoma cells (Dalloul et al., 1992) , its production by chronic lymphocytic leukaemia cells (Frishman et al., 1993) and Burkitt's lymphoma cells (Benjamin et al., 1994) , and its elevation in the sera of Hodgkin's patients (Trumper et al., 1994) .
IL-7 engagement of its receptor activates two main pathways, signal transducer and activator of transcription (STAT) 5 (Lin et al., 1995; van der Plas et al., 1996) of the JAK/STAT pathway and the phosphatidylinositol-3 kinase (PI3 kinase) pathway (Dibirdik et al., 1991; Dadi and Roifman, 1993; Venkitaraman and Cowling, 1994) . Both STAT5 and PI3 kinase have been implicated in cell-growth control and survival. Two nearly identical genes, STAT5A and STAT5B, encode two separate STAT5 polypeptides with similar, but nonidentical functions (Udy et al., 1997; Park et al., 1999) . Tyrosine kinase fusion proteins associated with human leukaemia can activate STAT5 in a wide variety of malignancies. For example, BCR/Abl in chronic myelogenous leukaemia, TEL/JAK2 in myeloproliferative disease, and TEL/ PDGFbR, TEL/Abl and HIP1/PDGFbR (reviewed in Levy and Gilliland, 2000) , as well as v-Abl activate this transcription factor. Constitutively activated STAT5A transforms haematopoietic cell lines to growth-factor independence (Onishi et al., 1998) . Interestingly, a role for IL-7 induction of STAT5 and survival has been shown in cutaneous T-cell lymphomas (Qin et al., 2001a, b) . Much is known about the molecular events initiating these pathways. Less is known about integration to downstream biology in vivo and the potential therapeutic benefit of targeting these events.
The effect of gene dosage on biology is well appreciated in the study of tumour suppressors in predisposing a cell to malignancy. Haploinsufficiency, the concomitant reduction in protein levels, is gaining significance in both tumour suppressor studies (Quon and Berns, 2001; Kemkemer et al., 2002) and in transcription factor biology (Seidman and Seidman, 2002) . Human haploinsufficiency of transcription factors can manifest as complex, multisystem syndromes with wide clinical variation, and at least 30 syndromes identified. The extensive catalogue of transcription factor families that demonstrate haploinsufficiency does not include members of the STAT family of transcription factors (Seidman and Seidman, 2002) . Our study of effectors that could ameliorate IL-7-mediated lymphoma development revealed that haploinsufficiency of receptor components as well as the STAT5 transcription factor could significantly modify the consequence of overexpression of IL-7.
IL-7 induced lymphoma development is affected by IL-7Ra copy number
Mice overexpressing IL-7 under the control of the immunoglobulin enhancer and promoter (Tg IL-7 mice) displayed accelerated mortality ( Figure 1a , left panel) compared to nontransgenic mice due to T-and Blymphoma development, with 100% mortality by 6 months of age as described previously (Rich et al., 1993) . IL-7-induced mortality was completely dependent on IL-7Ra, since mice that had homozygous disruption of IL-7Ra (IL-7Ra À/À ) showed no difference in survival in the absence or presence of the IL-7 transgene ( Figure 1a , right panel), with survival well beyond 8 months in all mice. More interestingly, we observed that mice heterozygous for the IL-7Ra subunit (IL-7Ra
), which had comparable lymphocyte cellularity to IL-7Ra wild-type (IL-7Ra þ / þ ) mice (data not shown), exhibited improved survival from IL-7-induced death ( Figure 1b ). Nearly half of Tg IL-7; IL-7Ra þ /À mice were alive at 8 months of age, while none of the Tg IL-7; IL-7Ra þ / þ mice survived to this age. 
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IL-7 induced lymphoma development is STAT5A/5B dose dependent
Since IL-7 activates STAT5, we acquired mice with disruption at both the STAT5A and STAT5B loci (Teglund et al., 1998) to test the necessity of this transcription factor effector in IL-7 signalling. While mice with compound homozygous disruption have multiple nonhaematopoietic and haematolymphoid defects (Socolovsky et al., 1998 (Socolovsky et al., , 1999 Teglund et al., 1998; Kieslinger et al., 2000; Sexl et al., 2000; Bradley et al., 2002; Bunting et al., 2002; Shelburne et al., 2002; Snow et al., 2002) , STAT5A/5B þ /À compound heterozygous mice had normal lifespans (Figure 2a, triangles) , lymphoid cellularity (Figure 2d ), T-cell development (data not shown) and bone marrow precursors that were normal in competitive repopulation assays (unpublished observations). This indicated no detectable consequence of reduction of STAT5 copy number on lymphoid development at steady state. When crossed to Tg IL-7 mice, STAT5A/5B þ /À compound heterozygous mice showed a striking amelioration of IL-7-induced mortality (Figure 2a, squares) compared to Tg IL-7; STAT5A/ 5B þ / þ mice (Figure 2a, circles) . Half of mice lacking a copy each of STAT5A and STAT5B that overexpressed IL-7 were still alive at 9 months of age, while none of the Tg IL-7; STAT5A/5B þ / þ mice lived beyond 6 months. It was possible that STAT5A/5B heterozygosity decreased transgene expression of IL-7 itself, and consequently, of disease induction. We measured IL-7 /5B copy number dependent. STAT5A/5B þ /À compound heterozygote targeted mice were crossed with Tg IL-7 mice and monitored twice monthly for lesions, node enlargement and survival over 9 months. Nontransgenic; STAT5A/5B þ /À , black triangles (n ¼ 13), Tg IL-7; STAT5A/5B þ /À , white squares, (n ¼ 10), Tg IL-7; STAT5A/5B þ / þ , black circles (n ¼ 5). STAT5A/5B and Tg IL-7 mice were backcrossed with C57BL/6 mice for a minimum of nine generations. (b) Quantitative PCR was performed with 37.5 ng DNase-treated RNA from thymocytes of the indicated genotypes, reverse transcribed with random hexamers and amplified with primers AATCGTGCTGCTCGCAAGTT and CACCAGTGTTTGTGTGCCTTGT with SYBR Green Master Mix and measured on an Applied Biosystems 7300 real-time PCR system. Transcripts were quantified against a serial titration of IL-7 cDNA standards.
. Values are mean7s.e.m. *Po0.05. (c) Immunoblot analysis of STAT5 expression in STAT5A/5B targeted mice. Lysates were prepared from thymocytes from the indicated mouse genotypes, normalized for total protein, resolved by SDS-PAGE, transferred and immunoblotted. Rabbit polyclonal antibodies to STAT5A and STAT5B (kindly provided by Dr Lothar Henninghausen, NIH, MD, USA) were used together at 1 : 10 000, mouse monoclonal antibody to a-tubulin (Sigma) was used at 1 : 5000 and visualized with anti-rabbit or anti-mouse HRP using enhanced chemiluminescence. (d) Spleens from the indicated mouse genotypes were removed, weighed and dispersed into singlecell suspension. Total cell counts of viable cells were performed by trypan blue exclusion. Nontransgenic; STAT5A/5B (Figure 2b) . Indeed, there appeared to be a significant elevation of IL-7 levels in these mice clearly indicating that increased survival in these mice was not due to STAT5 dose impairment of IL-7. We next examined the level of STAT5 in wild-type, heterozygous and homozygous STAT5A/5B-null thymocytes to determine whether STAT5 protein levels were affected by gene dosage. Immunoblot analysis showed that STAT5A/5B þ /À compound heterozygous mice had reduced levels of STAT5 present in the thymus compared to STAT5A/5B þ / þ mice (Figure 2c) . No polypeptide was detectable in STAT5A/5B À/À compound homozygous mice as expected. These data clearly indicated that STAT5 haploinsufficiency was manifest with reduced STAT5A/5B copy number.
We next assessed IL-7-induced splenomegaly as another indicator of disease development in these mice. Tg IL-7 mice showed a markedly elevated splenocyte cellularity (Figure 2d ) compared to nontransgenic littermates. Tg IL-7, STAT5A/5B þ /À compound heterozygous mice, however, had apparently lower IL-7-induced splenomegaly.
STAT5A/5B haploinsufficiency ameliorates lymphoma development
Histopathological analysis was performed on thymus, spleen and skin sections from nontransgenic, Tg IL-7; STAT5A/5B þ / þ and Tg IL-7; STAT5A/5B þ /À mice. Overexpression of IL-7 resulted in disorganized thymic architecture, the presence of subcapsular lymphomas in the spleen with a greatly expanded white pulp and infiltration of the dermal layers reminiscent of cutaneous lymphoma at late stages (Figure 3) . Age-matched Tg IL-7; STAT5A/5B þ /À mice, however, displayed fewer signs of aggressive disease with normal appearing thymic architecture and skin with greatly reduced lymphocyte infiltration (Figure 3) . The spleens did feature an atypical lymphoproliferation, but this subtle increase in lymphocytes was insufficient to meet usual diagnostic criteria for frank lymphoma. Although some surviving Tg IL-7; STAT5A/5B þ /À mice do eventually develop signs of disease at later time points, these data show that STAT5A/5B haploinsufficiency moderates IL-7-induced lymphoma development.
The categorization of pathways required during tumorigenesis is a promising avenue for the identification of novel targets for targeted therapeutics in treating malignancies. Genetic analyses of pathways in tumour models are a powerful means of assessing the usefulness of targeting a given molecule and its potential side effects. STAT5 is known to mediate cytokine-induced survival as well as proliferation in response to various cytokines (Lin and Leonard, 2000) . Indeed, as an effector of IL-7R function (Lin et al., 1995; van der Plas et al., 1996) , it can provide a proliferative or survival signal (Zamorano et al., 1998; Moriggl et al., 1999; Van Parijs et al., 1999; Lord et al., 2000) .
Haploinsufficiency has gained significance in helping elucidate the importance of specific molecules by genetics. Its role in transcription factors and disease is implicated in several syndromes, involving a broad class of these regulatory factors (Seidman and Seidman, 2002) . For example, haploinsufficiency of AML1 (Cai et al., 2000) and the Foxo1 forkhead transcription factor (Nakae et al., 2002) and Sairam, 2002) and even the erythropoietin receptor, a Type I cytokine receptor, (Jegalian et al., 2002) is increasingly recognized as physiologically relevant in mice. In addition, dose dependence has been described for the adaptor protein, Grb2, in regulating tissue architecture (Saxton et al., 2001) as well as in polyoma middle T antigen induction of mammary tumours (Cheng et al., 1998) . Few other examples of haploinsufficiency, particularly of transcription factors, affecting tumour development are known. We examined whether IL-7 receptor components and effectors, like STAT5, were necessary in IL-7-induced lymphoma development. IL-7-induced mortality was moderated in mice heterozygous for the IL-7Ra. Since IL-7Ra heterozygous mice had normal lymphoid development and cellularity, this suggests that IL-7Ra could be rate limiting for constitutive IL-7 action, such as in the Tg IL-7 lymphoma model. The effect of loss of one copy each of STAT5A and STAT5B on IL-7-induced lymphomas was similarly striking in ameliorating disease and improving survival. Our data showed that STAT5A/5B þ /À mice had a reduction in STAT5 protein levels indicating STAT5 haploinsufficiency in these mice.
We propose that IL-7-induced lymphoma development is dependent on signal strength that is affected by IL-7Ra and STAT5 levels. Thus, STAT5 transcription factor haploinsufficiency shows it is a rate-limiting effector for IL-7 in a tumour model. This contrasts with the absence of effect of loss of STAT5 on adult thymopoiesis (Kang et al., 2004) and on BCR-Abl transformation of bone marrow and myeloid cells (Sexl et al., 2000) . However, it mirrors the importance of STAT5 for the development of mammary cancer induced by SV40 T antigen (Ren et al., 2002) . This suggests that inhibition of STAT5 can have differing outcomes in ameliorating disease in different tumour development models and its utility has to be weighed in the lineage concerned. The apparent absence of bone marrow and lymphocyte abnormalities in nontransgenic; STAT5A/5B
þ /À mice also shows that as a therapeutic strategy, graded inhibition of STAT5A/5B to ameliorate haematolymphoid diseases that are sensitive to STAT5 levels may have few side effects.
Our findings show that a member of the STAT family of transcription factors, STAT5, can be included in the list of transcription factors whose haploinsufficiency can have a biological effect. Questions of whether STAT5A or STAT5B haploinsufficiency modifies IL-7 action by a qualitative or quantitative mechanism and the potential targets affected need further examination.
